公开(公告)号：US20240041497A1

公开(公告)日：2024-02-08

申请号：US18266639

申请日：2021-11-29

Applicant: Wook-Cheol Kim ,  Sadami Tsutsumi ,  NITTO SEIKO CO., LTD. ,  KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA

Inventor： Masakazu Ishihara ,  Yoshimitsu Ueno ,  Tomoaki Murata ,  Yukito Otsuki ,  Yusuke Kobayashi ,  Yoshinobu Oka ,  Wook-Cheol Kim ,  Tetsuo Aida ,  Sadami Tsutsumi

IPC: A61B17/58 ,  A61L31/02

CPC classification number: A61B17/58 ,  A61L31/022 ,  A61B2017/00004

Abstract: To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.

公开(公告)号：US11732311B2

公开(公告)日：2023-08-22

申请号：US16906115

申请日：2020-06-19

Applicant: National University Corporation University of Toyama

Inventor： Hideki Niimi ,  Shinya Otsuki ,  Isao Kitajima

IPC: C12Q1/689 ,  G16B30/00

CPC classification number: C12Q1/689 ,  G16B30/00

Abstract: The improved Tm mapping method using imperfect-match linear long quenching probes can accurately distinguish among and identify microorganisms at least at the genus level and often at the species level even in a real-time PCR instrument having measurement errors of Tm values between PCR tubes within ±0.5° C. Therefore, the Tm mapping method can be performed in almost all real-time PCR instruments and can identify unspecified infection-causing pathogenic microorganisms in about 4 hours after sample collection.

公开(公告)号：US20220125403A1

公开(公告)日：2022-04-28

申请号：US17427989

申请日：2020-02-02

Applicant: National University Corporation University of Toyama ,  GENERAL INCORPORATED ASSOCIATION MEDICAL INNOVATION CONSORTIUM

Inventor： Hideyuki HASEGAWA

IPC: A61B8/14 ,  A61B8/08 ,  A61B8/00 ,  G01S7/52

Abstract: Provided is a technique for improving spatial resolution contrast of an ultrasonic tomogram compared with a method based on a coherence between echo signals. The present invention provides an ultrasonic tomogram generation method including: an estimation step SA100 of estimating noise in echo signals of M channels output from an ultrasonic probe, which receives echoes of ultrasonic waves emitted from M (being a natural number of 2 or more) ultrasonic transducers and outputs an echo signal, and calculating a weight coefficient for emphasizing an echo from a reception focus according to a signal-to-noise ratio in the echo signals of the M channels; and a generation step SA110 of generating a beamformer representing an ultrasonic tomogram from the echo signals of the M channels, using the weight coefficient calculated in the estimation step SA100.

公开(公告)号：US10808302B2

公开(公告)日：2020-10-20

申请号：US15779971

申请日：2017-07-13

Applicant: SUMITOMO ELECTRIC INDUSTRIES, LTD. ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA

Inventor： Manabu Mizutani ,  Katsuhito Yoshida ,  Nozomu Kawabe ,  Seiji Saikawa

IPC: C22C23/02 ,  C22C23/00

Abstract: A magnesium alloy is provided that includes: 5.0 mass % or more and 15.0 mass % or less of Al; 2.5 mass % or more and 7.0 mass % or less of Sr; 0.05 mass % or more and less than 3.0 mass % of Ca; and 0.1 mass % or more and 0.6 mass % or less of Mn, with a remainder including Mg and inevitable impurities.

公开(公告)号：US10416165B2

公开(公告)日：2019-09-17

申请号：US15751792

申请日：2016-08-10

Applicant: National University Corporation University of Toyama

Inventor： Nobuyuki Kurosawa ,  Masaharu Isobe

IPC: C07H21/02 ,  C07H21/04 ,  C07K16/00 ,  A61K39/00 ,  C07K14/00 ,  G01N33/577 ,  C07K16/18 ,  C12N1/02 ,  C12N15/09 ,  G01N33/53 ,  C07K16/40 ,  C12N5/12 ,  C12N9/50 ,  C12N11/14

Abstract: A method for separating cells capable of producing target antigen-specific monoclonal antibodies (TASMAs) wherein a cell group including antibody-producing cells is immobilized using a reversible crosslinking agent having cell membrane-permeating properties. The immobilized cell group is subjected to cell membrane dissolution using a surface active agent; and the cell group is reacted with a labeling target antigen. In the stained cell group a that has reacted with the labeling target antigen is separated. A method to produce TASMAs by separating mRNA from the cell separated using the method; preparing cDNA and preparing antigen-specific monoclonal antibodies or fragments thereof from the prepared cDNA. Also provided are a method whereby at least one cell capable of producing TASMAs is separated and a method whereby said antibodies can be produced by using the separated cell. Threonine 18 phosphorylated p53 (pT18-p53) and threonine 68 phosphorylated CHK2 (pT68-CHK2) specific monoclonal antibodies are also disclosed.

公开(公告)号：US20180057860A1

公开(公告)日：2018-03-01

申请号：US15688473

申请日：2017-08-28

Applicant: Hokkaido Mitsui Chemicals Inc. ,  National University Corporation University of Toyama

Inventor： Homare Tabata ,  Hiroshi Minami ,  Hideki Niimi ,  Isao Kitajima ,  Tomohiro Ueno ,  Shiroh Hayashi ,  Masashi Mori

IPC: C12Q1/68 ,  C12N9/12 ,  C12P19/34

CPC classification number: C12Q1/689 ,  C12N9/1252 ,  C12P19/34 ,  C12Q1/68 ,  C12Q1/686 ,  C12Q1/6895 ,  C12Y207/07007

Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.

公开(公告)号：US09700572B2

公开(公告)日：2017-07-11

申请号：US14494637

申请日：2014-09-24

Applicant: Kracie Pharma, Ltd. ,  NATIONAL CANCER CENTER ,  National University Corporation University of Toyama

Inventor： Hiroyasu Esumi ,  Masafumi Ikeda ,  Chika Miyoshi ,  Shigetoshi Kadota ,  Toshiki Okubo ,  Satoshi Yomoda ,  Takafumi Fuse ,  Takanori Kawashima ,  Shigeki Chiba

IPC: A61K31/7048 ,  A61K31/7034 ,  A61K31/341 ,  A61K31/365 ,  A61K36/28

CPC classification number: A61K31/7048 ,  A61K31/341 ,  A61K31/365 ,  A61K31/7034 ,  A61K36/28 ,  A61K2300/00

Abstract: The present invention is intended to provide a novel anticancer agent which is effective to a cancer. After administering an agent prepared using burdock fruit extract to a pancreas cancer patient so that a dose of arctigenin was 100 mg or more per day, the tumor reducing effect was observed, and, in addition, lowering of tumor markers was confirmed. The present invention provides an anticancer agent containing arctigenin, wherein a dose of the arctigenin is 100 mg or more per day. In addition, the present invention provides the anticancer agent containing arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3.

公开(公告)号：US20170028065A1

公开(公告)日：2017-02-02

申请号：US15302863

申请日：2015-04-10

Applicant: National University Corporation University of Toyama ,  Kracie Pharma, Ltd. ,  National Cancer Center ,  Tokyo University of Science Foundation

Inventor： Hiroyasu Esumi ,  Kouji IKEDA ,  Katsuya TSUCHIHARA ,  Shigeki Chiba ,  Satoshi Yomoda ,  Takanori Kawashima ,  Toshiki Okubo ,  Yasuhiro TEZUKA ,  Kenta MURATA

IPC: A61K47/22 ,  A61K45/06 ,  A61K39/395 ,  A61K47/46 ,  A61K31/7068

CPC classification number: A61K47/22 ,  A61K31/122 ,  A61K31/137 ,  A61K31/16 ,  A61K31/216 ,  A61K31/225 ,  A61K31/277 ,  A61K31/336 ,  A61K31/352 ,  A61K31/365 ,  A61K31/366 ,  A61K31/416 ,  A61K31/427 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/551 ,  A61K31/5685 ,  A61K31/60 ,  A61K31/7068 ,  A61K31/7072 ,  A61K36/28 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/46 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/76 ,  A61K2300/00

Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.

Abstract translation: 本发明的目的是提供一种用于增强抗肿瘤效果，减轻副作用的抗癌剂，并且通过伴随使用具有抗癌作用的成分来进一步延长存活率。 将抗坏血酸蛋白和除抗坏血酸素以外的成分相结合的抗癌剂，其具有抗癌作用，其中抗癌剂可以是组合药物，也可以是由含有抗坏血青霉素的制剂和含有抗癌作用的成分的制剂构成的试剂盒， 并且伴随使用抗坏血酸素和具有抗癌作用的成分更强烈地抑制肿瘤生长并降低肿瘤中癌干细胞的比例，从而可以延长总存活时间并减轻由具有抗癌作用的成分引起的副作用 抗癌作用。

公开(公告)号：US20160257999A1

公开(公告)日：2016-09-08

申请号：US14969252

申请日：2015-12-15

Applicant: Hokkaido Mitsui Chemicals Inc. ,  National University Corporation University of Toyama

Inventor： Homare Tabata ,  Hiroshi Minami ,  Hideki Niimi ,  Isao Kitajima ,  Tomohiro Ueno ,  Shiroh Hayashi ,  Masashi Mori

IPC: C12Q1/68 ,  C12N9/12

CPC classification number: C12Q1/689 ,  C12N9/1252 ,  C12P19/34 ,  C12Q1/68 ,  C12Q1/686 ,  C12Q1/6895 ,  C12Y207/07007

Abstract: Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.

Abstract translation: 公开了一种耐热性DNA聚合酶制剂，其可以不利地降低使用基因扩增反应检测受试微生物的假阳性风险，因此即使当受试微生物的量为 因此从其收集的DNA的量非常小，并且可以以降低的成本生产。 还公开了使用本发明的制剂来快速，方便地且高灵敏度地定量或鉴定待检测物体的方法。

公开(公告)号：US20160222493A1

公开(公告)日：2016-08-04

申请号：US15092934

申请日：2016-04-07

Applicant: National University Corporation University of Toyama ,  Ahresty Corporation

Inventor： Seiji SAIKAWA ,  Gen OKAZAWA ,  Hiroshige NIWA ,  Kiyoshi TERAYAMA ,  Susumu IKENO ,  Emi YANAGIHARA ,  Shin ORII ,  Suguru TAKEDA

IPC: C22C21/08 ,  B22D21/00

CPC classification number: C22C21/08 ,  B22D21/007 ,  C22C21/02 ,  C22C21/04

Abstract: An Al—Mg—Si-based aluminum alloy includes 0.015 to 0.12 mass % of Sr, the aluminum alloy producing a cast metal structure in which Mg2Si is crystallized in a fine agglomerate form.

Abstract translation: Al-Mg-Si系铝合金包含0.015〜0.12质量％的Sr，该铝合金制造Mg2Si以细小的聚集体形式结晶的铸造金属结构体。